4 completed. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 1 | Completed 1 |
Follow IPI-926: new trials by email Literature Review of IPI-926 trials Research Report on IPI-926
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma FOLFIRINOX, IPI-926 - Pancreatic Cancer, Adenocarcinoma | Phase 1 | Completed | Andrew Ko | 15 | 2011-08-23 | 2017-08-08 |
| Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer IPI-926 and Cetuximab - Recurrent Head and Neck Cancer | Phase 1 | Completed | University of Colorado, Denver | 9 | 2011-04-01 | 2014-01-31 |
| A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer IPI-926 plus gemcitabine, Placebo plus gemcitabine - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 122 | 2010-04-01 | 2017-03-06 |
| A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies IPI-926 - Neoplasms | Phase 1 | Completed | Infinity Pharmaceuticals, Inc. | 94 | 2008-09-01 | 2012-06-21 |
Neoplasms (2) · Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Head and Neck Neoplasms (1)
Infinity Pharmaceuticals, Inc. (2) · Andrew Ko (1) · University of Colorado, Denver (1)
United States (4) · Canada (2)
Robert Ross, MD (2) · Andrew Ko, M.D. (1) · Antonio Jimeno, MD, PhD (1)